CLRB רווח למניה בשנים עשר החודשים האחרונים Cellectar Corp

Cellectar Biosciences (CLRB) integrates ESG principles into the production of radiopharmaceuticals, strictly adhering to bioethics and environmental controls. This TTM earnings per share chart demonstrates the market's valuation of management efficiency, where -3.60 represents the latest metric reading. The company has shifted its focus toward targeted therapeutic partnerships, although geopolitical tensions and sanctions complicate reagent logistics, threatening the certification of new drugs.

This indicator reflects the rolling efficiency of profit generation per ordinary share. By analyzing earnings per share over the last four quarters, an investor assesses the business's actual ability to create value. The metric strips the financial result of the influence of the total number of shares, revealing fundamental profitability. For Cellectar Biosciences (CLRB), this figure depends on clinical trial stages rather than market cycles. The stability of scientific patents renders profit dynamics independent of macroeconomic volatility.